Navitoclax (ABT-263)

Name: Navitoclax (ABT-263)
Brand: Selleck Chemicals
SKU: S1001
Rating: 5 (268 reviews)

For research use only.

Catalog No.S1001

268 publications

CAS No. 923564-51-6

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Selleck's Navitoclax (ABT-263) has been cited by 268 publications

Cancer Cell, 2021, S1535-6108(21)00492-X

PubMed: 34624218 ( click the link to review the publication )

Cancer Cell, 2021, S1535-6108(21)00338-X

PubMed: 34270926 ( click the link to review the publication )

Cell, 2019, 178(2):302-315.e23

PubMed: 31299200 ( click the link to review the publication )

Cell, 2019, 178(2):361-373

PubMed: 31204100 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Cell, 2019, 36(1):68-83

PubMed: 31257073 ( click the link to review the publication )

Cell Metab, 2019, 30(1):129-142

PubMed: 31155496 ( click the link to review the publication )

Cancer Discov, 2018, 8(12):1598-1613

PubMed: 30254092 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(2):112-117

PubMed: 29200207 ( click the link to review the publication )

Cancer Cell, 2017, 32(4):490-505.e10

PubMed: 29017059 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(3):407-414.e4

PubMed: 28017795 ( click the link to review the publication )

Nature, 2016, 538(7626):477-482

PubMed: 27760111 ( click the link to review the publication )

Nat Med, 2016, 22(3):262-9

PubMed: 26828195 ( click the link to review the publication )

Dev Cell, 2021, S1534-5807(21)00360-9

PubMed: 34004159 ( click the link to review the publication )

Cell Rep, 2021, 34(11):108870

PubMed: 33730585 ( click the link to review the publication )

Cell Rep, 2021, 36(1):109334

PubMed: 34233184 ( click the link to review the publication )

Haematologica, 2021, 10.3324/haematol.2021.278743

PubMed: 34162179 ( click the link to review the publication )

Oncogene, 2021, 10.1038/s41388-021-01910-6

PubMed: 34193942 ( click the link to review the publication )

Cancers (Basel), 2021, 13(16)4123

PubMed: 34439278 ( click the link to review the publication )

Cancers (Basel), 2021, 13(14)3464

PubMed: 34298678 ( click the link to review the publication )

Cell Death Dis, 2021, 12(4):406

PubMed: 33859162 ( click the link to review the publication )

Cell Death Discov, 2021, 7(1):275

PubMed: 34608124 ( click the link to review the publication )
Cell Death Dis, 2021, 12(8):741

PubMed: 34315868 ( click the link to review the publication )

Cell Death Dis, 2021, 12(1):54

PubMed: 33423045 ( click the link to review the publication )

Cell Death Dis, 2021, 12(1):121

PubMed: 33495462 ( click the link to review the publication )

Br J Cancer, 2021, 10.1038/s41416-021-01441-7

PubMed: 34088988 ( click the link to review the publication )

Mol Cancer Ther, 2021, molcanther.MCT-21-0474-A.2021

PubMed: 34667112 ( click the link to review the publication )

Mol Oncol, 2021, 10.1002/1878-0261.13060

PubMed: 34258881 ( click the link to review the publication )

Clin Sci (Lond), 2021, 135(15):1873-1895

PubMed: 34318888 ( click the link to review the publication )

Antioxidants (Basel), 2021, 10(6)956

PubMed: 34203664 ( click the link to review the publication )

Mol Cancer Res, 2021, 19(4):651-666

PubMed: 33443106 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(2)E752

PubMed: 33451095 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(8)3811

PubMed: 33917026 ( click the link to review the publication )

Sci China Life Sci, 2021, 10.1007/s11427-021-1933-7

PubMed: 34109475 ( click the link to review the publication )

Transl Oncol, 2021, 14(5):101048

PubMed: 33667892 ( click the link to review the publication )

Tissue Eng Regen Med, 2021, 18(5):841-850

PubMed: 34003467 ( click the link to review the publication )

BMC Complement Med Ther, 2021, 21(1):88

PubMed: 33750370 ( click the link to review the publication )

PLoS Comput Biol, 2021, 17(2):e1008630

PubMed: 33617523 ( click the link to review the publication )

Cell Death Dis, 2021, 12(1):121

PubMed: 33495462 ( click the link to review the publication )

Nat Commun, 2021, 12(1):1134

PubMed: 33602934 ( click the link to review the publication )

Nat Commun, 2021, 12(1):1281

PubMed: 33627663 ( click the link to review the publication )

NPJ Breast Cancer, 2021, 7(1):60

PubMed: 34040000 ( click the link to review the publication )

Nat Cell Biol, 2020, 4

PubMed: 32367049 ( click the link to review the publication )

Sci Transl Med, 2020, 15;12(539) pii: eaax3799

PubMed: 32295900 ( click the link to review the publication )

Cell Res, 2020, 27;1-16

PubMed: 32341413 ( click the link to review the publication )

Mol Cell, 2020, 7;S1097-2765(20)30269-0

PubMed: 32416067 ( click the link to review the publication )
Nat Commun, 2020, 11(1):752

PubMed: 32029722 ( click the link to review the publication )

Nat Commun, 2020, 11(1):259

PubMed: 31937780 ( click the link to review the publication )

Mol Syst Biol, 2020, 16(2):e8664

PubMed: 32073727 ( click the link to review the publication )

Blood Cancer J, 2020, 10(6):72

PubMed: 32591499 ( click the link to review the publication )

Aging Cell, 2020, 19(4):e13133

PubMed: 32175667 ( click the link to review the publication )

Elife, 2020, 2;9:e54954

PubMed: 32484436 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.33393

PubMed: 33186476 ( click the link to review the publication )

Eur J Cancer, 2020, 126:93-103

PubMed: 31927215 ( click the link to review the publication )

J Med Chem, 2020, 63(22):13733-13744

PubMed: 33197310 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2551

PubMed: 32911681 ( click the link to review the publication )

Cancers (Basel), 2020, 10;12(2) pii: E406

PubMed: 32050632 ( click the link to review the publication )

Breast Cancer Res, 2020, 22(1):130

PubMed: 33239070 ( click the link to review the publication )

Cell Death Dis, 2020, 11(10):854

PubMed: 33056980 ( click the link to review the publication )

Cell Death Dis, 2020, 8;11(6):443

PubMed: 32513939 ( click the link to review the publication )

Aging (Albany NY), 2020, 7;12(9):8221-8240

PubMed: 32379705 ( click the link to review the publication )

Cancer Sci, 2020, 111(10):3793-3801

PubMed: 32687646 ( click the link to review the publication )

Antioxidants (Basel), 2020, 9(11)E1143

PubMed: 33218059 ( click the link to review the publication )

Mol Cancer Res, 2020, molcanres.0586.2020

PubMed: 33288732 ( click the link to review the publication )

PLoS Negl Trop Dis, 2020, 14(3):e0008150

PubMed: 32196500 ( click the link to review the publication )

Front Pharmacol, 2020, 11:615505

PubMed: 33519480 ( click the link to review the publication )

Sci Rep, 2020, 14;10(1):222

PubMed: 31937836 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 4;526(3):612-617

PubMed: 32247610 ( click the link to review the publication )

Laryngoscope, 2020, 10.1002

PubMed: 31894587 ( click the link to review the publication )

Platelets, 2020, 10.1080/09537104.2020.1724276

PubMed: 32079453 ( click the link to review the publication )
Mol Biol Rep, 2020, 47(6):4849-4856

PubMed: 32424523 ( click the link to review the publication )

Biomater Sci, 2020, 8(8):2264-2273

PubMed: 32134074 ( click the link to review the publication )

Cancer Lett, 2020, S0304-3835(20)30635-2

PubMed: 33259900 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2020, S0360-3016(20)34731-3

PubMed: 33385497 ( click the link to review the publication )

PLoS One, 2020, 15(7):e0234103

PubMed: 32645016 ( click the link to review the publication )

Leuk Lymphoma, 2020, 1-5

PubMed: 32627634 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):537-548

PubMed: 31911540 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(14):14174-14188

PubMed: 32692721 ( click the link to review the publication )

J Hematol Oncol, 2020, 13(1):95

PubMed: 32677976 ( click the link to review the publication )

NPJ Breast Cancer, 2020, 6:30

PubMed: 32715085 ( click the link to review the publication )

Cancers (Basel), 2020, 12(8):E2137

PubMed: 32752193 ( click the link to review the publication )

Anat Cell Biol, 2020, 53(4):471-480

PubMed: 33361545 ( click the link to review the publication )

Cancers (Basel), 2020, 12(8):E2298

PubMed: 32824203 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2020, 15;106(4):867-877

PubMed: 31786278 ( click the link to review the publication )

Cell Rep, 2020, 32(2):107897

PubMed: 32668248 ( click the link to review the publication )

EMBO Mol Med, 2020, 12(12):e12391

PubMed: 33231937 ( click the link to review the publication )

Trop Life Sci Res, 2020, 31(3):1-13

PubMed: 33214852 ( click the link to review the publication )

Cell Rep, 2020, 31(13):107830

PubMed: 32610131 ( click the link to review the publication )

Free Radic Biol Med, 2020, 152:227-234

PubMed: 32217194 ( click the link to review the publication )

FASEB J, 2020, 10.1096/fj.201900218R

PubMed: 32619061 ( click the link to review the publication )

Mol Cell, 2019, 74(1):19-31

PubMed: 30878284 ( click the link to review the publication )

Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Sci Adv, 2019, 5(7):eaau9433

PubMed: 31392262 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0713

PubMed: 31409615 ( click the link to review the publication )
EMBO Mol Med, 2019, 11(10):e10769

PubMed: 31468706 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0775

PubMed: 31806643 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1398

PubMed: 31492749 ( click the link to review the publication )

Thyroid, 2019, 29(4):540-548

PubMed: 30869573 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 30860026 ( click the link to review the publication )

Oncogene, 2019, 38(1):47-59

PubMed: 30076411 ( click the link to review the publication )

Br J Pharmacol, 2019, 10.1111/bph.14773

PubMed: 31222722 ( click the link to review the publication )

J Med Chem, 2019, 62(15):6913-6924

PubMed: 31339316 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12841

PubMed: 31663663 ( click the link to review the publication )

Cell Death Dis, 2019, 10(5):342

PubMed: 31019203 ( click the link to review the publication )

FASEB J, 2019, 10.1096/fj.201900815RR

PubMed: 31408372 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.04.011

PubMed: 31155509 ( click the link to review the publication )

Stem Cell Res Ther, 2019, 10(1):86

PubMed: 30867061 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(23)

PubMed: 31801186 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5912

PubMed: 30976015 ( click the link to review the publication )

J Biol Chem, 2019, 294(3):875-886

PubMed: 30482844 ( click the link to review the publication )

Mol Pharmacol, 2019, 96(4):419-429

PubMed: 31467029 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:218

PubMed: 31462891 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:222

PubMed: 31467488 ( click the link to review the publication )

Prostate, 2019, 79(11):1347-1359

PubMed: 31228231 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):1251

PubMed: 31881855 ( click the link to review the publication )

BMC Cancer, 2019, 20(1):1

PubMed: 31892356 ( click the link to review the publication )

Cell Biosci, 2019, 9:60

PubMed: 31367332 ( click the link to review the publication )
Transl Oncol, 2019, 12(4):683-692

PubMed: 30844579 ( click the link to review the publication )

Photodiagnosis Photodyn Ther, 2019, 10.1016/j.pdpdt.2019.08.016

PubMed: 31430575 ( click the link to review the publication )

Cancer Biomark, 2019, 24(1):51-59

PubMed: 30614795 ( click the link to review the publication )

Nat Metab, 2019, 1(11):1074-1088

PubMed: 31799499 ( click the link to review the publication )

Cell Oncol (Dordr), 2019, 42(3):287-301

PubMed: 30859392 ( click the link to review the publication )

Immunity, 2018, 48(4):675-687

PubMed: 29653696 ( click the link to review the publication )

J Allergy Clin Immunol, 2018, 142(5):1647-1650.e3

PubMed: 30048671 ( click the link to review the publication )

Nat Commun, 2018, 9(1):215

PubMed: 29335437 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(19):10195-10215

PubMed: 30239926 ( click the link to review the publication )

Neuro Oncol, 2018, 20(2):203-214

PubMed: 29016820 ( click the link to review the publication )

Oncogene, 2018, 37(22):2936-2952

PubMed: 29520102 ( click the link to review the publication )

Cell Death Discov, 2018, 4:107

PubMed: 30479840 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )

Cell Death Dis, 2018, 9(7):713

PubMed: 29915306 ( click the link to review the publication )

Cell Death Dis, 2018, 92(10)

PubMed: 23640461 ( click the link to review the publication )

Cell Death Dis, 2018, 9(5):445

PubMed: 29670075 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):21

PubMed: 29343814 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):907

PubMed: 30185782 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 48(3):1123-1138

PubMed: 30041196 ( click the link to review the publication )

Mol Oncol, 2018, 12(3):287-304

PubMed: 29063678 ( click the link to review the publication )

Stem Cell Res Ther, 2018, 9(1):108

PubMed: 29669575 ( click the link to review the publication )

Antioxidants (Basel), 2018, 10.3390/antiox7110150

PubMed: 30373097 ( click the link to review the publication )

Biochemical Pharmacology, 2018, 10.1016/j.bcp.2018.01.031

PubMed: ( click the link to review the publication )

Sci Rep, 2018, 8(1):16822

PubMed: 30429524 ( click the link to review the publication )
Mar Drugs, 2018, 16(12)

PubMed: 30572618 ( click the link to review the publication )

Biomed Pharmacother, 2018, 107:139-145

PubMed: 30086460 ( click the link to review the publication )

Cell Cycle, 2018, 17(17):2175-2186

PubMed: 30198376 ( click the link to review the publication )

Toxicol In Vitro, 2018, 46:229-236

PubMed: 28947240 ( click the link to review the publication )

Oncotarget, 2018, 9(28):20075-20088

PubMed: 29732004 ( click the link to review the publication )

Oncotarget, 2018, 9(24):16701-16717

PubMed: 29682179 ( click the link to review the publication )

J Exp Med, 2018, 215(1):319-336

PubMed: 29263218 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(10):1226-1236

PubMed: 28945232 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(9):1116-1129

PubMed: 28846096 ( click the link to review the publication )

J Clin Invest, 2017, 127(2):635-650

PubMed: 28094768 ( click the link to review the publication )

Nat Commun, 2017, 8:16078

PubMed: 28714472 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1940

PubMed: 29208897 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1067

PubMed: 29057925 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(2):382-387

PubMed: 28028240 ( click the link to review the publication )

Cancer Res, 2017, 77(8):2018-2028

PubMed: 28202526 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3513-3526

PubMed: 28522750 ( click the link to review the publication )

Cancer Res, 2017, 77(9):2476-2487

PubMed: 28209615 ( click the link to review the publication )

J Cell Biol, 2017, 216(11):3655-3675

PubMed: 28877995 ( click the link to review the publication )

Cancer Res, 2017, 77(9):2512-2521

PubMed: 28202514 ( click the link to review the publication )

Aging Cell, 2017, 16(4):693-703

PubMed: 28401730 ( click the link to review the publication )

Cell Death Dis, 2017, 8(10):e3062

PubMed: 28981092 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2563-2571

PubMed: 28839001 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2178-2190

PubMed: 28611106 ( click the link to review the publication )

Cell Commun Signal, 2017, 15(1):16

PubMed: 28464919 ( click the link to review the publication )
Cell Discov, 2017, 3:16048

PubMed: 28101374 ( click the link to review the publication )

Dis Model Mech, 2017, 10(9):1109-1115

PubMed: 28883017 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(12):1632-1641

PubMed: 28713162 ( click the link to review the publication )

Int J Oncol, 2017, 10.3892/ijo.2017.3914

PubMed: 28350129 ( click the link to review the publication )

Biomed Pharmacother, 2017, 95:1574-1579

PubMed: 28950657 ( click the link to review the publication )

Anticancer Drugs, 2017, 28(10):1141-1149

PubMed: 28885267 ( click the link to review the publication )

Tumour Biol, 2017, 39(5):1010428317699120

PubMed: 28459212 ( click the link to review the publication )

Oncotarget, 2017, 8(18):29558-29573

PubMed: 28418907 ( click the link to review the publication )

Oncotarget, 2017, 8(49):86312-86324

PubMed: 29156797 ( click the link to review the publication )

Oncotarget, 2017, 8(34):57047-57057

PubMed: 28915653 ( click the link to review the publication )

Viruses, 2017, 9(10)

PubMed: 28946654 ( click the link to review the publication )

Nat Microbiol, 2016, 1:15034

PubMed: 27572165 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Autophagy, 2016, 12(7):1083-93

PubMed: 27172402 ( click the link to review the publication )

Clin Cancer Res, 2016, pii: clincanres.2827.2015

PubMed: 27126996 ( click the link to review the publication )

Leukemia, 2016, 30(2):351-60

PubMed: 26488112 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(6):1624-9

PubMed: 26811457 ( click the link to review the publication )

Cancer Res, 2016, 76(23):7001-7011

PubMed: 27671680 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Int J Cancer, 2016, 138(2):507-14

PubMed: 26260669 ( click the link to review the publication )

Anal Chem, 2016, 88(16):8050-7

PubMed: 27425825 ( click the link to review the publication )

Endocr Relat Cancer, 2016, 23(1):35-45

PubMed: 26483423 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(11):2915-2926

PubMed: 27913811 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(1):27-35

PubMed: 26575826 ( click the link to review the publication )
Cell Cycle, 2016, 15(3):394-402

PubMed: 26694174 ( click the link to review the publication )

PLoS One, 2016, 11(10):e0164250

PubMed: 27723829 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(4):1792-7

PubMed: 27613092 ( click the link to review the publication )

J Biomol Screen, 2016, 21(7):680-8

PubMed: 27245141 ( click the link to review the publication )

Mol Med Rep, 2016, 13(1):403-11

PubMed: 26548896 ( click the link to review the publication )

Data Brief, 2016, 6:710-4

PubMed: 26958630 ( click the link to review the publication )

Oncotarget, 2016, 7(50):82013-82027

PubMed: 27852038 ( click the link to review the publication )

Oncotarget, 2016, 7(1):845-59

PubMed: 26625317 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27153554 ( click the link to review the publication )

Oncotarget, 2016, 7(23):34453-71

PubMed: 27144341 ( click the link to review the publication )

EMBO Rep, 2015, 16(5):618-27

PubMed: 25739811 ( click the link to review the publication )

Cell Death Differ, 2015, 10.1038/cdd.2015.73

PubMed: 26045046 ( click the link to review the publication )

Int J Cancer, 2015, 137(12):2959-70

PubMed: 26096065 ( click the link to review the publication )

Breast Cancer Res, 2015, 17:26

PubMed: 25848915 ( click the link to review the publication )

Breast Cancer Res, 2015, 17(1):533

PubMed: 25778369 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e2034

PubMed: 26720343 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(1):298-306

PubMed: 25344583 ( click the link to review the publication )

Frontiers in Oncology, 2015, 4:368

PubMed: 25566506 ( click the link to review the publication )

Sci Rep, 2015, 5:14739

PubMed: 26446703 ( click the link to review the publication )

Ann Surg Oncol, 2015, 22(9):3079-86

PubMed: 25524010 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0120913

PubMed: 25811469 ( click the link to review the publication )

PLoS One, 2015, 10(1):e0116998

PubMed: 25615615 ( click the link to review the publication )

Microvasc Res, 2015, 101:72-81

PubMed: 26122935 ( click the link to review the publication )
Oncol Lett, 2015, 10(2):829-834

PubMed: 26622578 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26008975 ( click the link to review the publication )

Oncotarget, 2015, 6(29):27388-402

PubMed: 26317541 ( click the link to review the publication )

Oncotarget, 2015, 6(25):21557-71

PubMed: 26188358 ( click the link to review the publication )

Oncotarget, 2015, 6(17):15551-65

PubMed: 26036632 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26059440 ( click the link to review the publication )

Oncotarget, 2015, 6(34):36456-71

PubMed: 26474387 ( click the link to review the publication )

Sci Rep, 2015, 5:16406

PubMed: 26553339 ( click the link to review the publication )

J Clin Invest, 2014, 124(1):117-28

PubMed: 24292713 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):4737-52

PubMed: 25250573 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(41):14788-93

PubMed: 25267614 ( click the link to review the publication )

Chem Sci, 2014, 5, 2794–2803

PubMed: ( click the link to review the publication )

Int J Cancer, 2014, 136(3):688-98

PubMed: 24895203 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.21

PubMed: 24608435 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1028

PubMed: 24481442 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1291

PubMed: 24922075 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02798-13

PubMed: 24752266 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574 ( click the link to review the publication )

Skelet Muscle, 2014, 4(1):4

PubMed: 24484587 ( click the link to review the publication )

PLoS One, 2014, 9(10):e108371

PubMed: 25289887 ( click the link to review the publication )

PLoS One, 2014, ;9(6):e99404

PubMed: 24901320 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10237-50

PubMed: 25296978 ( click the link to review the publication )

Blood, 2013, 121(10):1850-7

PubMed: 23303820 ( click the link to review the publication )
Blood, 2013, 122(9):1587-98

PubMed: 23881917 ( click the link to review the publication )

Cell Death Differ, 2013, 20(11):1475-84

PubMed: 23832116 ( click the link to review the publication )

Haematologica, 2013,

PubMed: 23850807 ( click the link to review the publication )

Int J Cancer, 2013, 132(4):978-87

PubMed: 22821746 ( click the link to review the publication )

J Neurosci, 2013, 33(12):5195-207

PubMed: 23516285 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e883

PubMed: 24157877 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e742

PubMed: 23887633 ( click the link to review the publication )

Neoplasia, 2013, 15(5):568-78

PubMed: 23633928 ( click the link to review the publication )

Cell Cycle, 2013, 12(18):2960-8

PubMed: 23974105 ( click the link to review the publication )

PLoS One, 2013, 8(5):e64051

PubMed: 23691145 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 434(3):695-700

PubMed: 23602897 ( click the link to review the publication )

Exp Dermatol, 2013, 22(8):518-23

PubMed: 23802633 ( click the link to review the publication )

Helsinki Metropolia University, 2013, Jens Desloovere

PubMed: ( click the link to review the publication )

Cancer Res, 2012, 72(12):2949-56

PubMed: 22505651 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Cancer Lett, 2012, 339(2):288-97

PubMed: 23200668 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e351

PubMed: 22825469 ( click the link to review the publication )

Toxicol Sci, 2012, 128(1):79-91

PubMed: 22491427 ( click the link to review the publication )

J Biol Chem, 2012, 287(34):28598-608

PubMed: 22733819 ( click the link to review the publication )

Mol Biol Cell, 2012, 23(12):2240-52

PubMed: 22535522 ( click the link to review the publication )

Transfusion, 2012, 52(10):2094-103

PubMed: 22320126 ( click the link to review the publication )

Blood, 2011, 117(26):7145-54

PubMed: 21562047 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(12):3956-68

PubMed: 21652541 ( click the link to review the publication )

Cancer Res, 2011, 71(13):4518-26

PubMed: 21546570 ( click the link to review the publication )
PLoS One, 2011, 6(8):e21980

PubMed: 21829603 ( click the link to review the publication )

PLoS One, 2011, 6(9):e24590

PubMed: 21931768 ( click the link to review the publication )

Biochem Biophys Res Commun, 2011, 408(2):344-9

PubMed: 21514278 ( click the link to review the publication )

Clin Cancer Res, 2010, 16(16):4217-25

PubMed: 20601444 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Targets

Bcl-xL ^[1] (Cell-free assay)	Bcl-2 ^[1] (Cell-free assay)	Bcl-w ^[1] (Cell-free assay)
<=0.5 nM(Ki)	<=1 nM(Ki)	<=1 nM(Ki)

In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. ^[1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. ^[1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. ^[2]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
FL5.12	NYP0Wo9mS3m2b4TvfIlkcXS7IHHzd4F6	NH\CWG0zPCCq	MnfxSWM2OCB;IECuNFA1OiEQvF2=	NFH5dHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEi0NVg5Oid-MUi4OFE5QDJ:L3G+
FL5.12	MWDDfZRwfG:6aXPpeJkh[XO\|YYm=	M1TqbVI1KGh?	NILndVdGSzVyIE2gNE4xODV7IN88US=>	M4nNSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OESxPFgzLz5zOEi0NVg5OjxxYU6=
RS4:11	M1vFSWFxd3C2b4Ppd{Bie3OjeR?=	NYjDU4gxPiCq	NYHHdVl7TUN3MDC9JFAvODF2IN88US=>	NG\hUYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi4NVU3Pyd-MkS4PFE2Pjd:L3G+
FDC-P1	M3XZcWJEVC1{IHnubIljcXSrb36gZZN{[Xl?	MVOyOEBp	NGHUTHpKSzVyIE2gNE4xOTVizszN	NF;1SFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi4NVU3Pyd-MkS4PFE2Pjd:L3G+
NCI-H1963	NULkOIdCS3m2b4TvfIlkcXS7IHHzd4F6	NIPicIE1KGSjeYO=	M2DZcmlEPTBiPTCwMlAzPjZizszN	MlTxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2NEiyPVgoRjJ\|NES4Nlk5RC:jPh?=
NCI-H187	MnrkR5l1d3SxeHnjbZR6KGG\|c3H5	NHmwWlI1KGSjeYO=	Mo\aTWM2OCB;IECuNFM5PCEQvF2=	Mk\xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2NEiyPVgoRjJ\|NES4Nlk5RC:jPh?=
NCI-H1417	NUPlXnV2S3m2b4TvfIlkcXS7IHHzd4F6	NVm5WYJHPCCmYYnz	NH7XdlFKSzVyIE2gNE4xPTR{IN88US=>	NGDZRXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S0PFI6QCd-MkO0OFgzQTh:L3G+
FDC-P1	NWPtd4F{SkOOLYjMJIlvcGmkaYTpc44h[XO\|YYm=	NHSzeIMzPCCq	MnX0TWM2OCB;IECuNFYh\|ryP	MkDKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6OEG1OlcoRjJ2OEixOVY4RC:jPh?=
NCI-H146	NFnhdVhEgXSxdH;4bYNqfHliYYPzZZk>	MX60PEBp	NYq4SVdiTUN3MDC9JFAvODh4NzFOwG0>	M4LnTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OESxPFgzLz5zOEi0NVg5OjxxYU6=
RS4:11	M4HhVWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MnXZSWM2OCB;IECuNVEzKM7:TR?=	NVriOXVHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5NlYzPDdpPkK4PVI3OjR5PD;hQi=>
MOLT4	M4rFOGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MYTFR\|UxKD1iMD6zNFMh\|ryP	NIGzbFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEmyOlI1Pyd-Mki5NlYzPDd:L3G+
EoL-1-cell	MmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlTGTWM2OD1yLkCwOlY6KM7:TR?=	NGnvPZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
MV-4-11	NWjK[5dtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3KzbGlEPTB;MD6wNVU5PiEQvF2=	MmjxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NKM-1	NXHvZppZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NY\YVIZOUUN3ME2wMlAyPjl7IN88US=>	NIHXeI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
ML-2	NG[wXW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXy2NGNFUUN3ME2wMlAyQTh\|IN88US=>	NXzEZmpuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
BV-173	MmK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIOxbVdKSzVyPUCuNFI{OTRizszN	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
RS4-11	NYjGWWNvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnH5TWM2OD1yLkCyOVg4KM7:TR?=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HL-60	M3\3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MULJR\|UxRTBwMEK5NFgh\|ryP	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
KY821	MlvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MUnJR\|UxRTBwMEK5O\|Uh\|ryP	NXXVWI4yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
ECC10	M2r1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Ml3uTWM2OD1yLkCzO\|kzKM7:TR?=	MkLtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H720	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4\XUWlEPTB;MD6wOFAyOSEQvF2=	NYH2PZJvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
QIMR-WIL	NUP3eZdNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MV\JR\|UxRTBwMESyPFch\|ryP	NXr4eXVKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
KG-1	MlftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWDWdlRpUUN3ME2wMlA1PDh4IN88US=>	M1HIe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
TGW	M{XMXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkTXTWM2OD1yLkC0OlM{KM7:TR?=	NHzqd5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
ATN-1	NYr6eHZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVvJR\|UxRTBwMES3N\|Mh\|ryP	MnfhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
RH-18	NW\HNXdlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnHNTWM2OD1yLkC2NFQ5KM7:TR?=	MorHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
EW-18	M3XqVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYPJR\|UxRTBwME[4OFEh\|ryP	M4q0elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NB17	M3rOXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYDJR\|UxRTBwMEexNlQh\|ryP	NXf5XZlwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SK-NEP-1	MlHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NH7tdYFKSzVyPUCuNFczOTNizszN	MkDuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
P12-ICHIKAWA	NWj1eplRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4PUemlEPTB;MD6wO\|c4QCEQvF2=	MonKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
KARPAS-45	NXLOWJR3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NV:4cZdWUUN3ME2wMlA4QDF3IN88US=>	MmjPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
EW-3	MkfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MonzTWM2OD1yLkC4NFU{KM7:TR?=	Mon2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NB13	NYKzb49jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGjVXY5KSzVyPUCuNFgzODNizszN	NWDofoMxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H209	NU\FUnJGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYOycJhZUUN3ME2wMlA5PzB2IN88US=>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H1092	NXe0ToZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVnJR\|UxRTBwMUCyO\|Uh\|ryP	NGXhOII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NH-12	NFzBXWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVT4XY4{UUN3ME2wMlExPzR2IN88US=>	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
697	MnP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHXCSIpKSzVyPUCuNVA5OzlizszN	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
KE-37	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUXx[HVVUUN3ME2wMlEyOzdizszN	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
MOLT-4	NFHNdndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHGwcnBKSzVyPUCuNVUyPjlizszN	Ml7FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
CHP-134	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MorCTWM2OD1yLkG2N\|A3KM7:TR?=	NGXLSG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
D-283MED	NFrWPJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEHjV4VKSzVyPUCuNVc3QDZizszN	M4rWTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
LU-135	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYnJR\|UxRTBwMUi1OVIh\|ryP	NYrS[21zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
LU-134-A	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmnCTWM2OD1yLkG4OlcyKM7:TR?=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
EM-2	NXzLVIN5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Ml\MTWM2OD1yLkG5PVE5KM7:TR?=	M1jIUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
LU-139	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mk\HTWM2OD1yLkKwOFk5KM7:TR?=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
ALL-PO	NFzJd3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NV7sW3NDUUN3ME2wMlIyQTh6IN88US=>	M3XKZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NB12	NXjj[W9wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGLHd5hKSzVyPUCuNlMyOTVizszN	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
KP-N-YN	NGPKNlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVHJR\|UxRTBwMkO1O\|Mh\|ryP	M2HvU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
BEN	MnX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHj5WJZKSzVyPUCuNlM6PjhizszN	MkT3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
HCC1569	NXfrWFRyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnXWTWM2OD1yLkK1NVA3KM7:TR?=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HuO9	NUjJdmZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVf5fYxWUUN3ME2wMlI3PzF3IN88US=>	M1\iS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
WM-115	M2XRTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mn74TWM2OD1yLkK3O\|M5KM7:TR?=	M4XPR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
CCRF-CEM	M{jpZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEjjRZhKSzVyPUCuN\|M2OjlizszN	NWLVNFU1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
IST-SL1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3nHXmlEPTB;MD6zOVM1OyEQvF2=	Ml\FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
BE-13	M1;kN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXvJR\|UxRTBwM{[0OVkh\|ryP	MoDiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
COR-L88	M1nuPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkPmTWM2OD1yLkO2OVQh\|ryP	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
DOHH-2	NXL5U3J[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NX;pSJVNUUN3ME2wMlQyODJ\|IN88US=>	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
A704	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIPtb\|lKSzVyPUCuOFI3PyEQvF2=	NXz3XGJsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
KNS-81-FD	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIfxcIZKSzVyPUCuOFQxOTdizszN	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
RPMI-8226	MnrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4XIOmlEPTB;MD60OVY2OiEQvF2=	NETufYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
TGBC24TKB	MnTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGCxN4dKSzVyPUCuOFU4PzhizszN	M1LyTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H1304	NX\0[o1RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXTJR\|UxRTBwNE[xOVch\|ryP	NYS0VVYxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
MOLT-13	M1K4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGHtOIZKSzVyPUCuOFY3OTNizszN	M{myPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
EW-22	NG\NWGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlLsTWM2OD1yLkS2OlcyKM7:TR?=	M{XhWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
MS-1	NE\YRohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFflcJVKSzVyPUCuOFY6OzNizszN	NV\TfYhqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
RMG-I	NUjKS4x1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mn21TWM2OD1yLkS5OFY1KM7:TR?=	NFy0fYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NTERA-S-cl-D1	M4myXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUPJR\|UxRTBwNUCwNVkh\|ryP	MmLSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H1048	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MV3JR\|UxRTBwNUC5OVMh\|ryP	NViw[INvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SW1417	NILiV4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MV3JR\|UxRTBwNUW0N\|gh\|ryP	NYqzOpFiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
DB	NV;UUphrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUXpS25sUUN3ME2wMlU4ODhizszN	M16zbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
MEG-01	Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmPITWM2OD1yLkW4N\|Ih\|ryP	M1H0RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
EW-13	M2PVNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlHRTWM2OD1yLkW4N\|QyKM7:TR?=	NH7GSoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
LAMA-84	M{nu[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlvITWM2OD1yLkW5NlA4KM7:TR?=	MojsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
J-RT3-T3-5	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFnCUlhKSzVyPUCuOlA5ODhizszN	NVLaPVk1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
MOLT-16	Ml\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXzVUos{UUN3ME2wMlY2OjZ2IN88US=>	MlLBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
DU-4475	NWXkO3BlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnfRTWM2OD1yLk[1OFI4KM7:TR?=	NXX3WXR5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
HAL-01	NYHwVFJmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYLJR\|UxRTBwN{K1OFkh\|ryP	MkXrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
RD	MkW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MULJR\|UxRTBwN{W4PVkh\|ryP	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
OAW-28	NHT3XZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4Xtb2lEPTB;MD63PFM4KM7:TR?=	NX3ZTJVsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
HCC38	M1vOWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHrMSYFKSzVyPUCuPFAyQSEQvF2=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NMC-G1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3XSVmlEPTB;MD64NVEzOSEQvF2=	NVPabId2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
EW-16	NGLZcYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M37yb2lEPTB;MD64NVMzQCEQvF2=	M{O2RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
DU-145	M4nLO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWfJR\|UxRTBwOEm5NlMh\|ryP	M3TteVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
HPAF-II	NXvKW3dOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnP0TWM2OD1yLkmyOlI5KM7:TR?=	M4nzSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
A427	NHrxbFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHP4RmJKSzVyPUCuPVMxOjJizszN	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
PA-1	MlzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NV;JeWhmUUN3ME2wMlk2PjR{IN88US=>	MoTDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
OAW-42	M1fw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NG\2dI5KSzVyPUCuPVYyPDZizszN	NYjSbZU2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
L-428	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NV75[pYyUUN3ME2xMlAyOjVizszN	MlW1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
COLO-824	NInqe\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFflUGdKSzVyPUGuNFE4ODhizszN	NWK2VY9GRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
P30-OHK	MoXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{DyWGlEPTB;MT6wOFY5QCEQvF2=	MonrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H2170	NGPke5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnvhTWM2OD1zLkC2NlMh\|ryP	NWPCb4doRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
HCC2998	NYfnTGVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnyzTWM2OD1zLkC3NVM2KM7:TR?=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NB14	MlGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWHJem16UUN3ME2xMlE{PzR6IN88US=>	MnTPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
TGBC1TKB	Mn\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlvKTWM2OD1zLkG0NVUzKM7:TR?=	M4nvXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
KP-N-YS	NWTYV2FCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3zBZWlEPTB;MT6xOlI{PiEQvF2=	NWrJWnB6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
CAL-120	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXLJR\|UxRTFwMU[0Nlkh\|ryP	NVi3NXc1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SBC-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIDqOldKSzVyPUGuNVkxPTNizszN	NWjp[pp2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
C32	M4rBWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnHvTWM2OD1zLkG5NFg5KM7:TR?=	NHjC[no9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
HCC2157	M{XKfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYHI[5dHUUN3ME2xMlE6PDl2IN88US=>	MoPqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
COLO-792	M1rD[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M33LWmlEPTB;MT6yNFA4OSEQvF2=	Ml21QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
ES7	MlnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NEmzfXBKSzVyPUGuNlc6PTFizszN	NVPkV3V3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
HEL	NVPmNZY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3;iTWlEPTB;MT6zNVAzQSEQvF2=	NFuxNnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
ES4	NG[yc5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NE\PUoNKSzVyPUGuN\|Q6QThizszN	MnXSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-SNU-1	NXvhNoNjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M33qWmlEPTB;MT6zOlU2PSEQvF2=	M4fEcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
MDA-MB-415	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MomyTWM2OD1zLkO4PFUh\|ryP	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H2342	NXTkVXd5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXfzNXV6UUN3ME2xMlQxOjZ7IN88US=>	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NB69	NWXObpFuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mmq5TWM2OD1zLkS2NlcyKM7:TR?=	NGTYTFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
D-247MG	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MV;JR\|UxRTFwNUGxNlIh\|ryP	NV;oVWZMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SCC-4	NX\FPIpPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NV7WTmJyUUN3ME2xMlU6QDh5IN88US=>	NFTO[W49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
HuH-7	NIHoVYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUC1SZVRUUN3ME2xMlY4Ojl\|IN88US=>	NH\jcIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
A388	M3XYbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGOyZmpKSzVyPUGuOlg4OjRizszN	NUPhUYt2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
Calu-3	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NF7QTo1KSzVyPUGuO\|A3QTdizszN	Mm\XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H1648	NXqyWYhPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1jrWGlEPTB;MT63NVQyQCEQvF2=	NE\zWmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NCI-H2052	M2XsXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlniTWM2OD1zLkeyNlAyKM7:TR?=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
Ramos-2G6-4C10	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2nYUmlEPTB;MT63N\|Y2PiEQvF2=	NEGxdpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
DEL	NYjURZB4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{jOUWlEPTB;MT63OFY6OiEQvF2=	NHLyTlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SNU-423	MlfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIqwbWJKSzVyPUGuO\|gyPTdizszN	NHHQWpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
COR-L23	MlTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M333SWlEPTB;MT63PVg4PCEQvF2=	NHiwUoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
OMC-1	NUH0b2ZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MX\JR\|UxRTFwOE[wNVYh\|ryP	NYGyd283RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
EW-11	M{e4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVvRW2ZpUUN3ME2xMlk2PjV5IN88US=>	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HSC-3	NYj4VJY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIT6N3FKSzVyPUGuPVY{PjVizszN	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
MLMA	MnnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFzldHJKSzVyPUGuPVY3PzdizszN	NIjRWnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
RCM-1	MmG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYT1UYJYUUN3ME2yMlAxOzl7IN88US=>	MkXRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
MFE-280	M4fmNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2eyUGlEPTB;Mj6wNlg1QCEQvF2=	NHnweJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
ES8	M{LCUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2HvPWlEPTB;Mj6yOVQ4OSEQvF2=	NVvoRohRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
TE-11	M{e2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MofhTWM2OD1{LkK5OFc{KM7:TR?=	NFXUWJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
HuO-3N1	NGr5[VJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MY\JR\|UxRTJwNEi3PEDPxE1?	M2DIOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
MHH-NB-11	NIS5Z\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NW\QPFVQUUN3ME2yMlUyOTV6IN88US=>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
TGBC11TKB	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NEnX[XRKSzVyPUKuOVc3QDFizszN	M4e1RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
HOP-92	NI\sTGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3O3fGlEPTB;Mj61PFc1OyEQvF2=	MnrRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
IGR-1	NGPQe5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3vvV2lEPTB;Mj62NlA{PSEQvF2=	NEjYPI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
GOTO	NIGxNHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHvIelBKSzVyPUKuOlU{PzdizszN	NF35doE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NCI-H1650	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWDJR\|UxRTJwN{KyNVUh\|ryP	NYDwTWM1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H1581	NHuxPYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3vNXWlEPTB;Mj63PVY5OSEQvF2=	Mn;ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H2405	NGn4SmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUf4UpYxUUN3ME2yMlgzPzh{IN88US=>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
U-118-MG	NVLvUZVNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFTMcXpKSzVyPUKuPVY1QTFizszN	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
DoTc2-4510	MmTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGK2eHZKSzVyPUOuNFE1OTdizszN	MmLZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H596	NHXwcGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYjJR\|UxRTNwMES5PVch\|ryP	NHHxXHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
MPP-89	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnH5TWM2OD1\|LkC1OlY3KM7:TR?=	M{TOclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
GCIY	NWLoUYNwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NECwSIpKSzVyPUOuNlA1QTFizszN	NGG5fWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SW626	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mnv6TWM2OD1\|LkK0OVQ{KM7:TR?=	NGS2e2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
OCI-AML2	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYr0SlFsUUN3ME2zMlMyOjd{IN88US=>	MnjHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NBsusSR	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGG5c5dKSzVyPUOuN\|Q6OzhizszN	M2exSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
AN3-CA	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlHxTWM2OD1\|LkS0NlM5KM7:TR?=	NXLl[IloRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
EFM-19	MlPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MoGyTWM2OD1\|LkS4N\|M6KM7:TR?=	NX;BSoFKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
RVH-421	MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFrtRplKSzVyPUOuOVY5PzdizszN	M1nh[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
5637	M3LUXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M17NZWlEPTB;Mz62NVExOyEQvF2=	NYrsPXU6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
PANC-08-13	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3juOmlEPTB;Mz62N\|Q4OiEQvF2=	M2TBZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
H9	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVLE[HlpUUN3ME2zMlY4OTR2IN88US=>	NHn3Vmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
KARPAS-299	NUTyW3BjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mof1TWM2OD1\|Lk[3N\|YyKM7:TR?=	M2XtTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
TE-5	M4DQN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NITNUoxKSzVyPUOuO\|A4ODlizszN	MoDBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NOS-1	Mnv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYPqSJN3UUN3ME2zMlc6QDN2IN88US=>	NVPleHFQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
HH	NGDqU3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXizVnhXUUN3ME2zMlg{QDZ6IN88US=>	NHvtboc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
769-P	Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4n4WGlEPTB;Mz64PVUyKM7:TR?=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
CHP-212	NYXlT2RMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUfBOm5yUUN3ME2zMlkzPTR7IN88US=>	Mn32QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H82	MorwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1TJfWlEPTB;Mz65OVk{PiEQvF2=	NEXhWYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
Mo-T	NX63NmhQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYPJR\|UxRTRwMESzNVIh\|ryP	NXnPTXpURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
BB65-RCC	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4LVU2lEPTB;ND6wOFM6QSEQvF2=	M2[5UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SW1990	MnfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MljlTWM2OD12LkC1PVA5KM7:TR?=	NILoUYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
LK-2	MkezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXi3VHRVUUN3ME20MlEyOjl\|IN88US=>	NYHsZ3JuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
ES5	M{DDVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MojmTWM2OD12LkGzPVg2KM7:TR?=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
JVM-3	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NH3qcG9KSzVyPUSuNVgzOjJizszN	NInTcHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
RPMI-7951	NGfnfXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3f5WWlEPTB;ND6yNlQyOyEQvF2=	MmfGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
Calu-6	NF7TfG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWT5N5JCUUN3ME20MlI4QDhzIN88US=>	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
LC-2-ad	M2m1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYjJR\|UxRTRwMkm1Olgh\|ryP	NHHqdGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SW954	NWjkW2NQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVvJR\|UxRTRwMkm2OkDPxE1?	MoLKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
H-EMC-SS	M1TOR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{HQd2lEPTB;ND6zNVg{OSEQvF2=	NWDEXoFXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
ES3	Mkf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGHEbpdKSzVyPUSuN\|U1PDFizszN	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
no-11	M{HzSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYjKNldZUUN3ME20MlM2PTV2IN88US=>	Mk\IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
LAN-6	NGPCbVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFfV[WRKSzVyPUSuOFUyQDlizszN	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
FTC-133	NGL4dplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mn:5TWM2OD12LkWzPVUh\|ryP	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
8505C	MknoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIO2PWdKSzVyPUSuOVQzOyEQvF2=	M{OzblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SW620	Mnf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVjJR\|UxRTRwNUewOVch\|ryP	M4jIelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
BCPAP	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXTJR\|UxRTRwNkO0PFEh\|ryP	M2HDclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SK-LU-1	NVLJfXlQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYPoXHhtUUN3ME20MlY3ODh7IN88US=>	NIHBSIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NCI-H1623	NWrENJBxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NW\weGZRUUN3ME20MlcxOjJ6IN88US=>	MkDtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
C2BBe1	M4LFdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXTJR\|UxRTRwN{SwNFgh\|ryP	MmHMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
GP5d	NV;vbXg{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYjJR\|UxRTRwN{izPFgh\|ryP	M{Tid\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NB6	MnztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGm1RXJKSzVyPUSuPFYzODRizszN	M17IPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
MDA-MB-157	M2PEXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHLU[4RKSzVyPUSuPFg4PiEQvF2=	NVO4XW1qRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
UMC-11	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkDoTWM2OD12Lki4PVY1KM7:TR?=	NYS1Z2xRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
HCC1419	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVfjNmZ3UUN3ME20MlkxODZ\|IN88US=>	MoLGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H2029	M2LPTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mn\yTWM2OD12Lkm0NVg2KM7:TR?=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
LXF-289	MlLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYDJR\|UxRTVwMEO3NVkh\|ryP	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
KINGS-1	NEftbXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1LMdGlEPTB;NT6wO\|c1PCEQvF2=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HD-MY-Z	NGT0epNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmnwTWM2OD13LkKzPVY6KM7:TR?=	MlPGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
ESS-1	NFvyT4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmXaTWM2OD13LkK1OVk4KM7:TR?=	NYXnNHg1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
GI-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mof6TWM2OD13LkK3PVI3KM7:TR?=	NEm5[Jc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
RPMI-2650	NHHpTHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmjZTWM2OD13LkO2NVYh\|ryP	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
IA-LM	NIXpbWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{P1TWlEPTB;NT6zPVg4OSEQvF2=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
KP-4	NWLuT3NHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MoTsTWM2OD13LkS2N\|M1KM7:TR?=	MofzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
G-402	NISySXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnHwTWM2OD13LkWxPFY2KM7:TR?=	MkTOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
OS-RC-2	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnKyTWM2OD13LkWyOlA1KM7:TR?=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H1155	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUDJR\|UxRTVwNUS5OVUh\|ryP	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
OE19	MnznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mn24TWM2OD13Lk[4OlI1KM7:TR?=	MkfDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
U-2-OS	M17nUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVK5OGNTUUN3ME21Mlg6ODF\|IN88US=>	NWDTfWpMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SCC-15	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlLITWM2OD13LkmzOlYzKM7:TR?=	NUTISnN6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H630	NGnQfG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYjJR\|UxRTVwOUm0NFQh\|ryP	M{L3elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
PFSK-1	MnXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVrJR\|UxRTZwMEWyOVkh\|ryP	NXLzWZlHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H1770	MmHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MoTaTWM2OD14LkKwPFc1KM7:TR?=	Mk\QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
SK-MEL-3	MlmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXrS[FRpUUN3ME22MlQzQTF3IN88US=>	MkHvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
LB1047-RCC	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3jxOGlEPTB;Nj60O\|YzPSEQvF2=	NETDO449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NCI-H446	NXjQbFB7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlHGTWM2OD14Lk[yPVI2KM7:TR?=	MkixQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
SW780	MoPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWHMbJRXUUN3ME22MlcxOTh3IN88US=>	NXPEN3pnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NEC8	M1rFW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGe1WJdKSzVyPU[uO\|Y3OyEQvF2=	NHywWpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NOMO-1	M1vHOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NF6wc\|JKSzVyPU[uO\|gyOTFizszN	MmPUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
COLO-668	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2O0[mlEPTB;Nj64OFM5PyEQvF2=	Ml22QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
MC116	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWe2NVBwUUN3ME22Mlk{QDl5IN88US=>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HCC1937	NFToU3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFntTndKSzVyPU[uPVkzPTFizszN	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-N87	NYrQUoVST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmrxTWM2OD15LkG5Nlk{KM7:TR?=	M{GweVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
COLO-320-HSR	NEfPd3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEDkUYlKSzVyPUeuNlI4OzhizszN	NFvkVoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
HCC1806	NXT5R4ZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXriNXhwUUN3ME23MlI3ODR2IN88US=>	NED4ZpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
OVCAR-3	Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXrpendNUUN3ME23MlM{ODN6IN88US=>	NEHEd\|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NUGC-3	NIPTdppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXf5eZBYUUN3ME23MlM6Pjl2IN88US=>	MmPrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
SW1783	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mni4TWM2OD15LkSzNVc2KM7:TR?=	NIi3Zng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
GCT	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3;xNmlEPTB;Nz61OlkxPiEQvF2=	NWXy[XZWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H2126	NHTmTYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2fSOGlEPTB;Nz63N\|YzPSEQvF2=	NIXZS3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
MEL-HO	NXzxNm5lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWPJR\|UxRTdwN{ewOVQh\|ryP	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
CAPAN-1	NUfKNWhmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHHvN49KSzVyPUeuO\|c{PTdizszN	NXf1W29lRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SW756	M3HtOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXzJR\|UxRTdwN{izN\|Mh\|ryP	Mm\NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
SKG-IIIa	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1qwRWlEPTB;Nz64NVg6OiEQvF2=	MnrJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
HCE-T	MkjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MUnJR\|UxRTdwOEe3PFMh\|ryP	MlTTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
Ca-Ski	M12xNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{TjZWlEPTB;Nz65PVM5OyEQvF2=	M2rHelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
COLO-684	MoP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MojOTWM2OD16LkCxPFE5KM7:TR?=	NFvH[FM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
KYSE-70	NHLUW\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NH\JNpVKSzVyPUiuNFc4OjlizszN	MnK0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
TI-73	NV3ORY5xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHvVc2NKSzVyPUiuNlU5PTFizszN	M1;PcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
BT-20	NVT3NIFuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFqxWGpKSzVyPUiuNlYxPTJizszN	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
MHH-ES-1	NV\tVJcyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NETtUZRKSzVyPUiuOVE5OzRizszN	NWHX[2E5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
TE-12	M4rRfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHLH[5pKSzVyPUiuOVk6OzFizszN	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
YH-13	NYfEVZB5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIr1PJJKSzVyPUiuOlExODhizszN	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SF126	M1n5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{XINWlEPTB;OD64N\|g3PSEQvF2=	MofVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
J82	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NETuPGNKSzVyPUiuPVAxOzhizszN	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
RCC10RGB	NX3lRYJGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVWy[XhFUUN3ME24Mlk6PTZzIN88US=>	NEjpW2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SK-UT-1	MmDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXTJR\|UxRTlwMES5OFUh\|ryP	M1e5SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
LB2241-RCC	NHrS[IpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVjJR\|UxRTlwMUmxN\|ch\|ryP	MnPiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
LB996-RCC	M17RWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkfuTWM2OD17LkG5PFkh\|ryP	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
EPLC-272H	NGG5VmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkLzTWM2OD17LkO3OlU4KM7:TR?=	Mn\FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
CTV-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWrEPYdHUUN3ME25MlU3PTN{IN88US=>	M1\rVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
HSC-2	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWfJR\|UxRTlwNUe1OUDPxE1?	NYfnPIx6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SK-MEL-28	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXe1b4xiUUN3ME25MlYyQDl\|IN88US=>	NHXLfmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
MMAC-SF	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1PnUWlEPTB;OT62PFc2KM7:TR?=	MkT1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
CP50-MEL-B	Mn\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVriNXBDUUN3ME25Mlc2Pzh{IN88US=>	NYLYWmlbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
HT-1080	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYfJR\|UxRTlwN{e3N\|kh\|ryP	NH3KV449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
HEC-1	NUHGe\|F5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFzseWJKSzVyPUGwMlM{PTJizszN	NXG4cZY4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
AGS	M1\MOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NF\SSItKSzVyPUGwMlM4PCEQvF2=	NFrxRnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
GAMG	NH7IeJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4DuW2lEPTB;MUCuOVE3OiEQvF2=	NX3iPZFXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SW48	M{TxVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWLzSJdTUUN3ME2xNE42OTh7IN88US=>	MkLNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
U031	MliyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MoXaTWM2OD1zMD61PVA5KM7:TR?=	MnjXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
OVCAR-5	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmTsTWM2OD1zMD62OFI6KM7:TR?=	M1H5O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SF295	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NH;hSnBKSzVyPUGwMlY4ODRizszN	NIDWcnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
BHT-101	MnfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkXmTWM2OD1zMD63NVc4KM7:TR?=	MnzmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
VMRC-RCZ	MmDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4jPe2lEPTB;MUGuN\|IxOSEQvF2=	NHnLclE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
ACHN	MoHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NV65dFlxUUN3ME2xNU41OjFzIN88US=>	Mn7FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H526	NXTmU3BoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXHJR\|UxRTFzLkWwOFMh\|ryP	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
MN-60	NHrSc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGLuWZdKSzVyPUGxMlU{QSEQvF2=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H2291	NWHDWYhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUjJR\|UxRTFzLkW0OlYh\|ryP	NEXlTGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SCC-25	NHnzcZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmjjTWM2OD1zMT63OVU3KM7:TR?=	NUH5XmI{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SK-MEL-2	M2KxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHL3eGpKSzVyPUGxMlc3OzdizszN	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SN12C	NX;QUoNMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGDEeXBKSzVyPUGxMlk{PTVizszN	MkPVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H69	NVfUS5hYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVr0fGVpUUN3ME2xNk41OjN2IN88US=>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
ME-180	MnLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NH:2fXFKSzVyPUGyMlcxPTRizszN	M1joTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
MC-IXC	M1\5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NX;VSpp6UUN3ME2xNk44PTF6IN88US=>	Mki2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H2347	MomzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUHEPFlGUUN3ME2xNk44PjF2IN88US=>	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
M059J	MkjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXrmSWlSUUN3ME2xNk44PzJ5IN88US=>	M1rHd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
A2058	M3XXT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGrOeXNKSzVyPUGyMlg3QDFizszN	Ml3pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
VA-ES-BJ	M1jVXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MoHpTWM2OD1zMj64O\|g2KM7:TR?=	NGTI[4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
Ca9-22	Moj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1LkPGlEPTB;MUKuPVQ2OSEQvF2=	M1\jN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
KNS-42	MkT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2ezcWlEPTB;MUKuPVk5PCEQvF2=	NE\INYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
LoVo	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHnWdI1KSzVyPUGzMlI{OTNizszN	M4mxfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
AM-38	NGHzTXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4Ky[mlEPTB;MUOuNlU3PiEQvF2=	NGq4fnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NB5	MkLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MV7JR\|UxRTF\|LkO3OVIh\|ryP	NXXpfVBKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
L-363	M1\1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{D0fGlEPTB;MUOuOFA{OyEQvF2=	NFHEWFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SK-MEL-30	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M173S2lEPTB;MUSuNFY1PSEQvF2=	NX\uU4VQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H1563	MoHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnrBTWM2OD1zND62NFM6KM7:TR?=	NVv2OJAzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H2228	NGr2VFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVHJR\|UxRTF2Lk[wO\|ch\|ryP	NHfX[YM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
MFM-223	M1u2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MoD4TWM2OD1zNT6xPFE{KM7:TR?=	NXuyd2ZiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
LB831-BLC	M{HLSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWrJR\|UxRTF3LkK3Olch\|ryP	NIjGVGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SW872	MnvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYrJR\|UxRTF3LkOwPFYh\|ryP	NGSyTXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NCI-H522	M1G0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnLnTWM2OD1zNT6zN\|A3KM7:TR?=	NUHOTFBnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
EW-1	MlfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHG1PYdKSzVyPUG1MlU1PjJizszN	NFu3XY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
HN	NWTYbVJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHzFU3VKSzVyPUG1MlU6PDJizszN	NHPu[pc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SW837	NXT4VGFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2iwZmlEPTB;MUWuO\|g1PyEQvF2=	NVO4ZWQzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SCC-9	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWXJR\|UxRTF3LkixNVQh\|ryP	M2nhUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
MKN7	NIDjNJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlXYTWM2OD1zNT65O\|MzKM7:TR?=	M3Pyb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
KYSE-410	NU\hb3NqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEHrcJRKSzVyPUG2MlU6OSEQvF2=	MlLEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
SK-N-DZ	M3THeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFW3XWdKSzVyPUG2MlYyOTZizszN	M1[2bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
COR-L105	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnTMTWM2OD1zNj62OVI5KM7:TR?=	M4PWfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
LB2518-MEL	M{XEVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUjJR\|UxRTF4LkizPFkh\|ryP	NYOxXGVxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
OVCAR-4	NYLkTnFuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYHJR\|UxRTF4Lki4OlIh\|ryP	M1v3O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
TK10	NYHYNml4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFzEWoVKSzVyPUG2Mlk1PzNizszN	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
KNS-62	NIHpdpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHHzbZdKSzVyPUG2Mlk4PzdizszN	NYi2cnNXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
RPMI-8866	MmiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mnn4TWM2OD1zNz6xO\|MzKM7:TR?=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HuP-T4	NU\uS\|ZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUPEflZtUUN3ME2xO{4zPDl3IN88US=>	M37Be\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
CGTH-W-1	NHi2O\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUiyZ5EyUUN3ME2xO{42OjF7IN88US=>	MmTpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
T-24	NEWwOGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnznTWM2OD1zNz61N\|Q4KM7:TR?=	Mlm2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
HT-3	NVLlcFV1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmnsTWM2OD1zNz61PVE1KM7:TR?=	NWDnR2NQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
KS-1	M1Hie2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFLINJlKSzVyPUG3MlY4OyEQvF2=	NXf1do9YRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H1792	NGH1[\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGfjNXJKSzVyPUG3Mlc6QCEQvF2=	MmnDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
ABC-1	NXq2NJY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkXUTWM2OD1zNz64NVQyKM7:TR?=	Mn\VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
BPH-1	M1XwUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mon5TWM2OD1zOD6xOlg2KM7:TR?=	Mk\CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
A431	Mk\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHjHNYZKSzVyPUG4MlQyOjdizszN	NEH4UXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
T98G	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUnkWFVuUUN3ME2xPE42OTV5IN88US=>	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
BHY	NH;l[VlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIK2VodKSzVyPUG4Mlg3QSEQvF2=	M1K3N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
Capan-2	M1zkTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{LIfGlEPTB;MUiuPVA4QCEQvF2=	NVjtblliRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
MDA-MB-175-VII	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFrz[41KSzVyPUG4MlkzODlizszN	M2HnTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
CAL-27	M1;G[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXXJR\|UxRTF7LkC0PFch\|ryP	NWGyVFNVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
AsPC-1	NIHPVpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHHKT25KSzVyPUG5Mlg3PTdizszN	NHnT[2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
KU812	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4TIcWlEPTB;MUmuPVU4OyEQvF2=	M4LRSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H441	M{LERWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NILSTnNKSzVyPUKwMlAxOSEQvF2=	MlfiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
Mewo	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4f2TmlEPTB;MkCuNVI5QCEQvF2=	MoeyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
SK-MEL-24	M4DjTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFjVNYRKSzVyPUKwMlE1PzdizszN	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H727	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFO0Xo5KSzVyPUKwMlI4ODRizszN	NHjGb4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
EKVX	NUDDe2xxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mln5TWM2OD1{MD62NFYh\|ryP	M{DOblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
RT-112	MlrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mnm0TWM2OD1{MD62NVIzKM7:TR?=	NIXQU249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
CAMA-1	M3fJTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NH6ySoRKSzVyPUKwMlk5ODNizszN	NIjBfWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SW900	M1Tj[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MY\JR\|UxRTJzLkCxOFkh\|ryP	M2\EO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H23	NI\ZfFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmDOTWM2OD1{MT6xNlc4KM7:TR?=	M3:5UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SK-PN-DW	NWL2PJhsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NF[yfG9KSzVyPUKxMlE3PDlizszN	Mn\SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
BB30-HNC	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWW2cXlTUUN3ME2yNU4zPzR3IN88US=>	MojmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
VM-CUB-1	NHn5TZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXPQcYQ6UUN3ME2yNU4{PTN4IN88US=>	NFzhPZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
IST-MEL1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MV7JR\|UxRTJzLkO2PVIh\|ryP	NUfCVJYxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
CTB-1	M2PsNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXKxXY1{UUN3ME2yNU41PzV3IN88US=>	NX:1[IpURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
LCLC-103H	M4HxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NY\sVnRZUUN3ME2yNk4yPTh{IN88US=>	NUfveGx3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
PANC-03-27	MnnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXu0cFlxUUN3ME2yNk42OTZ7IN88US=>	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HTC-C3	NVno[2RGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NELWcZZKSzVyPUKyMlU2PTVizszN	MnPCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
TE-8	M4PoRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXzJR\|UxRTJ\|LkK1OlUh\|ryP	NVLu[2xMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H292	Mk\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NEmySFRKSzVyPUK1MlM2OzZizszN	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
COLO-680N	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXLJR\|UxRTJ3Lk[zNlkh\|ryP	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
KYSE-520	NGX3XFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHfXNotKSzVyPUK1MlY1PCEQvF2=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NB10	NWq0VIdGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2TCPGlEPTB;Mk[uN\|EyPyEQvF2=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H661	NYrIT2JrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXH0bGY{UUN3ME2yOk41PzF\|IN88US=>	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
GMS-10	M3LwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkfnTWM2OD1{Nj64OlM5KM7:TR?=	NUDsPZRXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H2122	M{TaVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUXJR\|UxRTJ4Lkm5PVgh\|ryP	NWnpSFk2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
OVCAR-8	NYDqSI5VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NH;qdXdKSzVyPUK3MlA3OzhizszN	M{PtVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
DJM-1	M1u0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYD5cYN2UUN3ME2yO{4yPDV2IN88US=>	MkHMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
UACC-893	NEDCOJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUnaO5lCUUN3ME2yO{46QDd6IN88US=>	NV3nZ4g3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
C8166	NGeyTVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXjhV5NxUUN3ME2yPE43QTN6IN88US=>	Ml3wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H1693	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NV7mTmdxUUN3ME2yPE43QTd3IN88US=>	MnHwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
TYK-nu	NE\DbI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2ja[GlEPTB;M{CuNFM1PSEQvF2=	NHWxfJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SW1710	NXHwU5JpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXfJR\|UxRTNyLkGyOkDPxE1?	NWX6V4xJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
A375	M{jJeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2fvc2lEPTB;M{CuN\|I1OyEQvF2=	M{TFXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
HMV-II	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIHZb2ZKSzVyPUOxMlM2QTJizszN	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H2087	M{H1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYXJR\|UxRTNzLk[zOVIh\|ryP	NIPqWFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
CAL-54	MoLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{nZTmlEPTB;M{GuO\|I1OSEQvF2=	NFnyN\|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
HCC70	NH;nSXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlvVTWM2OD1\|Mj6xN\|g4KM7:TR?=	NYPKNVNuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
ES1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NF3EXnhKSzVyPUOyMlMxPjJizszN	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H1355	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHn5fI5KSzVyPUOzMlIxPCEQvF2=	MlzzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
CFPAC-1	NUPNUZhKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWi0V4VDUUN3ME2zN{4zOzN{IN88US=>	M{\6d\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
MKN28	NEjrdmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NV3rUlNLUUN3ME2zN{4{QDB7IN88US=>	NYSwdXk3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
HDLM-2	NF34fWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NULPXldpUUN3ME2zN{43QTNzIN88US=>	NHPvV4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
PANC-10-05	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NF\qfHVKSzVyPUO0MlExOTRizszN	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SAS	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWPs[WRwUUN3ME2zOE41PTZ3IN88US=>	NHzRNGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
HCC1395	NX\td4t{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUPvUZk4UUN3ME2zOE44OTh4IN88US=>	NVjSNlhmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
8305C	M3HmXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1K1U2lEPTB;M{WuPFQyPSEQvF2=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
KM12	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlvnTWM2OD1\|Nj63OVQ4KM7:TR?=	NYfzdFB5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SW1116	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NICwbnRKSzVyPUO3MlU6QTJizszN	NIO0VZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SK-MEL-1	NGm5fodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWDJR\|UxRTN6LkOzPFkh\|ryP	NETTZZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
HCC2218	MmfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlfwTWM2OD1\|OD62OVE6KM7:TR?=	MlPhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
T84	NVLF[HNpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYLJR\|UxRTN6Lke0NFkh\|ryP	MlnvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
ETK-1	M2P6WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIDnbYpKSzVyPUO5MlAzOiEQvF2=	M1X3SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
COLO-800	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVnJR\|UxRTN7LkO4Olgh\|ryP	NUfGS4VTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
CAL-12T	MmHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXqyRohmUUN3ME2zPU42OjhzIN88US=>	NV3l[5ZyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
ACN	NHXSUmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGnufldKSzVyPUSwMlQ6OTFizszN	NHr3bmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SJSA-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVTBcWR[UUN3ME20NU4yPTl4IN88US=>	NICzV449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
PSN1	NXnOZVZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEjOTZdKSzVyPUSxMlE4PDlizszN	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
D-566MG	Mn60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MUfJR\|UxRTRzLkKwPFYh\|ryP	NX\HdZk4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
EGI-1	NHHoT5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHOyfodKSzVyPUSyMlQzQCEQvF2=	MkDJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
A204	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWTaWo1tUUN3ME20Nk43Ozh6IN88US=>	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
Saos-2	NHfVfJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M37afmlEPTB;NEKuPFM3QSEQvF2=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SNU-C2B	NYnKV4VTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYXyRncxUUN3ME20N{43QDd6IN88US=>	M3Xt[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
HLE	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2mwdWlEPTB;NESuNFg2PiEQvF2=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SW1463	NWj4THJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4PKbmlEPTB;NESuPVk4OSEQvF2=	NV;zVW04RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
DSH1	NXHiTVRXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mn;JTWM2OD12NT6wNFM{KM7:TR?=	MoC0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
MCF7	NH;sVGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXrXWWVRUUN3ME20OU42ODVzIN88US=>	NGq0d4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
K5	MkfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGLZVZRKSzVyPUS1Mlk1ODVizszN	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H358	M{S3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWXJR\|UxRTR5LkKxOUDPxE1?	M3TuXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H2030	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYDJR\|UxRTR5LkKzO\|Qh\|ryP	M2\ZblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SW948	NYXBbXhxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkWyTWM2OD12Nz60OlQh\|ryP	NYrwPFJrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
BALL-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVTJR\|UxRTR5Lk[xOlgh\|ryP	NVPFZ2N2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
TE-9	MoXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3r5OmlEPTB;NEeuPVU5OSEQvF2=	M4m5U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SK-N-FI	NFrhbJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYfjXFhVUUN3ME20PE4xOzV6IN88US=>	MkHLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
KALS-1	M3q5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NETRVWlKSzVyPUS4MlEzQDlizszN	NXXZSYQ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
HO-1-N-1	NUHZe2xtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnzpTWM2OD12OD63OFQ2KM7:TR?=	M3vsc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H2452	Ml7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MoT5TWM2OD12OT6xNVUzKM7:TR?=	M3jp[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
OC-314	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYHEcJFbUUN3ME20PU43QDN2IN88US=>	NF\Uc\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	STAT3 / pSTAT3 / STAT6 / pSTAT6 / Mcl-1 / Cleaved Mcl-1 / Bcl-xl / Bim / puma / Bik / Bax / PARP / c-Myc; PubMed: 26811457 Proc Natl Acad Sci U S A (A) Western blot analysis of expressions of STAT3/p-STAT3 and STAT6/p-STAT6 as well as antiapoptotic members (Bcl-2, Bcl-xL, and Mcl-1) after 48 h of treatments in HDLM-2 cells. (B) Western blot analysis of expressions of proapoptotic proteins (Bim, Puma, Bik, Bax, and p-Bad) as well as caspase cascade molecules (PARP and c-Myc) after 48 h of treatments. β-Actin was used as an input control. caspase3 / cleaved caspase 3; PubMed: 24481442 Cell Death Dis (b) (i) N/TERT, (ii) SINCE and (iii) SINEG2 cells were either untreated (0 μM/DMSO) or treated with increasing doses of Navitoclax (ABT-263; 0.025–30 μM) and were incubated for 24 h. Next, cells were collected and whole-cell lysates were prepared and immunoblotted against anti-full-length Caspase 3 (∼35 kDa) antibody, whereas β-actin (∼42 kDa) was used as a protein-loading control. Apoptosis was assessed through detecting the cleaved bands of Caspase-3 (∼19, 17 kDa).	26811457 24481442
Growth inhibition assay	Cell viability; PubMed: 25685063 Cancer Cell Int (C) Hcc827, (D) H292, and (E) H1993 cells were treated with increasing concentrations of albendazole or mebendazole in the presence of navitoclax (0, 1, 2, and 4 μM). Viability was determined after 1 day.	25685063

In vivo

When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. ^[2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. ^[2]

Protocol

Kinase Assay: ^[1]	- Collapse Affinity determination: Binding affinities (K_i or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research: ^[1]	- Collapse Cell lines: SCLC cell lines Concentrations: 0-1 μM Incubation Time: 48 hours Method: Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO₂. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 ⁴) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice Dosages: 100 mg/kg/d Administration: Administered via p.o. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (102.6 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+corn oil For best results, use promptly after mixing.	4mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Navitoclax (ABT-263) SDF

Molecular Weight	974.61
Formula	C₄₇H₅₅ClF₃N₅O₆S₃
CAS No.	923564-51-6
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1(CCC(=C(C1)CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)NC(CCN5CCOCC5)CSC6=CC=CC=C6)S(=O)(=O)C(F)(F)F)C7=CC=C(C=C7)Cl)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04480086	Active not recruiting	Drug: Mivebresib\|Drug: Navitoclax\|Drug: Ruxolitinib	Myelofibrosis (MF)	AbbVie	March 17 2021	Phase 1
NCT04454658	Recruiting	Drug: ABBV-744\|Drug: Navitoclax\|Drug: Ruxolitinib	Myelofibrosis (MF)	AbbVie	November 11 2020	Phase 1
NCT04041050	Recruiting	Drug: Navitoclax\|Drug: Ruxolitinib\|Drug: Celecoxib	Myeloproliferative Neoplasm	AbbVie	November 8 2019	Phase 1
NCT03181126	Completed	Drug: Navitoclax\|Drug: Chemotherapy\|Drug: Venetoclax	Acute Lymphoblastic Leukemia (ALL)\|Lymphoblastic Lymphoma	AbbVie	November 27 2017	Phase 1
NCT02520778	Active not recruiting	Drug: Navitoclax\|Drug: Osimertinib	Advanced Lung Non-Squamous Non-Small Cell Carcinoma\|Metastatic Lung Non-Squamous Non-Small Cell Carcinoma\|Stage III Lung Non-Small Cell Cancer AJCC v7\|Stage IIIA Lung Non-Small Cell Cancer AJCC v7\|Stage IIIB Lung Non-Small Cell Cancer AJCC v7\|Stage IV Lung Non-Small Cell Cancer AJCC v7	National Cancer Institute (NCI)	March 31 2016	Phase 1
NCT02591095	Completed	Drug: ABT-263	Platinum-resistant or Refractory Ovarian Cancer	Centre Francois Baclesse\|ARCAGY/ GINECO GROUP\|French Cancer Research Hospital Program	January 2016	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?
Answer:
S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.
Question 2:
Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?
Answer:
According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Selective Bcl-2 Inhibitor

ABT-199 (GDC-0199) : Bcl-2-selective, K_i<0.01 nM.
Bcl-2 Inhibitor in Clinical Trial

Obatoclax Mesylate (GX15-070) : Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.
Classic Bcl-2 Inhibitor

ABT-737 : BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

Related Bcl-2 Products

MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
Venetoclax (ABT-199)

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with K_i of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Venetoclax is reported to induce cell growth suppression, apoptosis, cell cycle arrest, and autophagy in triple negative breast cancer MDA-MB-231 cells. Phase 3.

Features:Re-engineered version of ABT-263 (Navitoclax).
ABT-737

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. ABT-737 induces mitochondrial pathway apoptosis and mitophagy. Phase 2.
Obatoclax Mesylate (GX15-070)

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Features:Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.
Sabutoclax

Sabutoclax (BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
(R)-(-)-Gossypol acetic acid

(R)-(-)-Gossypol (AT-101) acetic acid, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. AT-101 simultaneously triggers apoptosis and a cytoprotective type of autophagy. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Navitoclax (ABT-263)